SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance

Abstract

Aim: Because mutations of splicing factor 3B subunit-1 (SF3B1) have been identified in 4% of pancreatic ductal adenocarcinoma (PDAC) patients, we investigated the activity of new potential inhibitors of SF3B1 in combination with gemcitabine, one of the standard drugs, in PDAC cell lines.

Methods: One imidazo[2,1-b][1,3,4]thiadiazole derivative (IS1) and three indole derivatives (IS2, IS3 and IS4), selected by virtual screening from an in-house library, were evaluated by the sulforhodamine-B and wound healing assay for their cytotoxic and antimigratory activity in the PDAC cells SUIT-2, Hs766t and Panc05.04, the latter harbouring the SF3B1 mutations. The effects on the splicing pattern of proto-oncogene recepteur d’origine nantais (RON) and the gemcitabine transporter human equilibrative nucleoside transporter-1 (hENT1) were assessed by PCR, while the ability to reduce tumour volume was tested in spheroids of primary PDAC cells.

Results: The potential SF3B1 modulators inhibited PDAC cell proliferation and prompted induction of cell death. All compounds showed an interesting anti-migratory ability, associated with splicing RON/ΔRON shift in SUIT-2 cells after 24 h exposure. Moreover, IS1 and IS4 potentiated the sensitivity to gemcitabine in both conventional 2D monolayer and 3D spheroid cultures, and these results might be explained by the statistically significant increase in hENT1 expression (P < 0.05 vs. untreated control cells), potentially reversing PDAC chemoresistance.

Conclusion: These results support further studies on new SF3B1 inhibitors and the role of RON/hENT1 modulation to develop effective drug combinations against PDAC.

Keywords

Pancreatic ductal adenocarcinoma / gemcitabine / indole derivatives / anti-proliferative activity / anti-migratory activity / SF3B1 / RON / hENT1

References

[1] Siegel RL,Jemal A.Cancer statistics, 2020.CA Cancer J Clin2020;70:7-30

[2] Khalaf N,Abrams HR.Burden of pancreatic cancer: from epidemiology to practice.Clin Gastroenterol Hepatol2021;19:876-84

[3] Rahib L,Aizenberg R,Fleshman JM.Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.Cancer Res2014;74:2913-21

[4] Kleeff J,Apte M.Pancreatic cancer.Nat Rev Dis Primers2016;2:16022

[5] Giovannetti E,Frampton AE,Firuzi O.Never let it go: stopping key mechanisms underlying metastasis to fight pancreatic cancer.Semin Cancer Biol2017;44:43-59

[6] Tanaka M,Probst P.Meta-analysis of recurrence pattern after resection for pancreatic cancer.Br J Surg2019;106:1590-601

[7] Caparello C,Garajova I.FOLFIRINOX and translational studies: towards personalized therapy in pancreatic cancer.World J Gastroenterol2016;22:6987-7005 PMCID:PMC4988311

[8] Singh RR.New treatment strategies for metastatic pancreatic ductal adenocarcinoma.Drugs2020;80:647-69 PMCID:PMC7466866

[9] El Hassouni B,Liu DSK.Pharmacogenetics of treatments for pancreatic cancer.Expert Opin Drug Metab Toxicol2019;15:437-47

[10] Beatty GL,Lyssiotis CA.The biological underpinnings of therapeutic resistance in pancreatic cancer.Genes Dev2021;35:940-62 PMCID:PMC8247606

[11] Sciarrillo R,Assaraf YG.The role of alternative splicing in cancer: from oncogenesis to drug resistance.Drug Resist Updat2020;53:100728

[12] Alsafadi S,Battistella A.Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage.Nat Commun2016;7:10615 PMCID:PMC4743009

[13] Cai J,Groulx N.Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells.Cancer Res2008;68:2349-57

[14] Wojtuszkiewicz A,Maas MJ,Jansen G.Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance.Expert Opin Drug Metab Toxicol2015;11:673-89

[15] Wang BD.Aberrant RNA splicing in cancer and drug resistance.Cancers (Basel)2018;10:458 PMCID:PMC6266310

[16] Yoshida K.Splicing factor mutations and cancer.Wiley Interdiscip Rev RNA2014;5:445-59

[17] Effenberger KA,Jurica MS.Modulating splicing with small molecular inhibitors of the spliceosome.Wiley Interdiscip Rev RNA2017;8:10.1002/wrna.1381 PMCID:PMC5253128

[18] Zhang D.A comprehensive overview of structure-activity relationships of small-molecule splicing modulators targeting SF3B1 as anticancer agents.ChemMedChem2020;15:2098-120

[19] Eskens FA,Burger H.Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.Clin Cancer Res2013;19:6296-304

[20] Gao Y.Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells.ACS Chem Biol2013;8:895-900 PMCID:PMC3657302

[21] Xargay-Torrent S,Rosich L.The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.Oncotarget2015;6:22734-49 PMCID:PMC4673195

[22] Wan Y,Yan C,Tang Z.Indole: a privileged scaffold for the design of anti-cancer agents.Eur J Med Chem2019;183:111691

[23] Dadashpour S.Indole in the target-based design of anticancer agents: a versatile scaffold with diverse mechanisms.Eur J Med Chem2018;150:9-29

[24] Parrino B,Carnevale I.Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.Eur J Med Chem2019;161:154-78

[25] Cascioferro S,Petri GL.2,6-disubstituted imidazo[2,1-b][1,3,4]thiadiazole derivatives as potent staphylococcal biofilm inhibitors.Eur J Med Chem2019;167:200-10

[26] Parrino B,Cascioferro S.1,2,4-Oxadiazole topsentin analogs as staphylococcal biofilm inhibitors targeting the bacterial transpeptidase sortase A.Eur J Med Chem2021;209:112892

[27] Carbone A,Parrino B.Thiazole analogues of the marine alkaloid nortopsentin as inhibitors of bacterial biofilm formation.Molecules2020;26:81 PMCID:PMC7795195

[28] Sivaprasad G,Prabavathy VR.Synthesis and anti-microbial activity of pyrazolylbisindoles--promising anti-fungal compounds.Bioorg Med Chem Lett2006;16:6302-5

[29] Leboho TC,van Otterlo WA,de Koning CB.The synthesis of 2- and 3-aryl indoles and 1,3,4,5-tetrahydropyrano[4,3-b]indoles and their antibacterial and antifungal activity.Bioorg Med Chem Lett2009;19:4948-51

[30] Li J,Xu R.Indole compounds with N-ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: synthesis and biological evaluation.Medchemcomm2019;10:1935-47 PMCID:PMC7478157

[31] Battaglia S,Da Settimo F.Indole amide derivatives: synthesis, structure-activity relationships and molecular modelling studies of a new series of histamine H1-receptor antagonists.Eur J Med Chem1999;34:93-105

[32] Patel DV,Kanhed AM.Further studies on triazinoindoles as potential novel multitarget-directed anti-Alzheimer's agents.ACS Chem Neurosci2020;11:3557-74

[33] Toumi A,Hamden K.Synthesis, antidiabetic activity and molecular docking study of rhodanine-substitued spirooxindole pyrrolidine derivatives as novel α-amylase inhibitors.Bioorg Chem2021;106:104507

[34] Xue S,Gao R,Li Z.Synthesis and antiviral activity of some novel indole-2-carboxylate derivatives.Acta Pharm Sin B2014;4:313-21 PMCID:PMC4629079

[35] Carbone D,Cascioferro S.1,2,4-oxadiazole topsentin analogs with antiproliferative activity against pancreatic cancer cells, targeting GSK3β kinase.ChemMedChem2021;16:537-54

[36] Cascioferro S,Di Sarno V.New 1,2,4-oxadiazole nortopsentin derivatives with cytotoxic activity.Mar Drugs2019;17:35 PMCID:PMC6357034

[37] Li Petri G,El Hassouni B.Biological evaluation of the antiproliferative and anti-migratory activity of a series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole derivatives against pancreatic cancer cells.Anticancer Res2019;39:3615-20

[38] Cascioferro S,Parrino B.Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells.Eur J Med Chem2020;189:112088

[39] Cascioferro S,Parrino B.3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole derivatives as new anticancer agents in the treatment of pancreatic ductal adenocarcinoma.Molecules2020;25:329 PMCID:PMC7024338

[40] Li Petri G,Randazzo O.New imidazo[2,1-b][1,3,4]thiadiazole derivatives inhibit FAK phosphorylation and potentiate the antiproliferative effects of gemcitabine through modulation of the human equilibrative nucleoside transporter-1 in peritoneal mesothelioma.Anticancer Res2020;40:4913-9

[41] Randazzo O,Mantini G."Open sesame?”: biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity in the uptake and cytotoxicity of gemcitabine in pancreatic cancer.Cancers (Basel)2020;12:3206 PMCID:PMC7692081

[42] Sastry GM,Day T,Sherman W.Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments.J Comput Aided Mol Des2013;27:221-34

[43] Greenwood JR,Sullivan AP.Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution.J Comput Aided Mol Des2010;24:591-604

[44] Protein data bank. Available from: https://pdb101.rcsb.org [Last accessed on 22 Sep 2021]

[45] Olsson MHM,Rostkowski M.PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions.J Chem Theory Comput2011;7:525-37

[46] Wolber G.LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters.J Chem Inf Model2005;45:160-9

[47] Perricone U,Seidel T,Padova A.The use of dynamic pharmacophore in computer-aided hit discovery: a case study.Methods Mol Biol2018;1824:317-33

[48] Friesner RA,Repasky MP.Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.J Med Chem2006;49:6177-96

[49] Carbone A,Di Vita G.Synthesis and antiproliferative activity of thiazolyl-bis-pyrrolo[2,3-b]pyridines and indolyl-thiazolyl-pyrrolo[2,3-c]pyridines, nortopsentin analogues.Mar Drugs2015;13:460-92 PMCID:PMC4306947

[50] Iwamura T,Ide K.Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9.Jpn J Cancer Res1987;78:54-62

[51] Owens RB,Nelson-Rees WA.Epithelial cell cultures from normal and cancerous human tissues.J Natl Cancer Inst1976;56:843-9

[52] Meijer LL,Caparello C.Plasma miR-181a-5p downregulation predicts response and improved survival after FOLFIRINOX in pancreatic ductal adenocarcinoma.Ann Surg2020;271:1137-47

[53] Le Large TYS,El Hassouni B.Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.J Exp Clin Cancer Res2021;40:91 PMCID:PMC7941981

[54] Sciarrillo R,El Hassouni B.Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.EBioMedicine2019;39:215-25 PMCID:PMC6355829

[55] Sciarrillo R,Kooi IE.Using RNA-sequencing to detect novel splice variants related to drug resistance in in vitro cancer models.J Vis Exp2016;54714: PMCID:PMC5226372

[56] Cretu C,Cook A.Structural basis of splicing modulation by antitumor macrolide compounds.Mol Cell2018;70:265-73.e8

[57] Finci LI,Huang X.The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action.Genes Dev2018;32:309-20 PMCID:PMC5859971

[58] Maguire SL,Wai P.SF3B1 mutations constitute a novel therapeutic target in breast cancer.J Pathol2015;235:571-80 PMCID:PMC4643177

[59] Biankin AV,Kassahn KS.Australian Pancreatic Cancer Genome InitiativePancreatic cancer genomes reveal aberrations in axon guidance pathway genes.Nature2012;491:399-405 PMCID:PMC3530898

[60] Dvinge H,Abdel-Wahab O.RNA splicing factors as oncoproteins and tumour suppressors.Nat Rev Cancer2016;16:413-30 PMCID:PMC5094465

[61] Shiraishi Y,Okada A.SF3B1ness score: screening SF3B1 mutation status from over 60,000 transcriptomes based on a machine learning approach.bioRxiv2019;

[62] Seiler M,Agrawal AA.Cancer Genome Atlas Research NetworkSomatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types.Cell Rep2018;23:282-96.e4 PMCID:PMC5933844

[63] Darman RB,Agrawal AA.Cancer-associated SF3B1 hotspot mutations induce cryptic 3' splice site selection through use of a different branch point.Cell Rep2015;13:1033-45

[64] Logan-Collins J,Yu P.Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.Cancer Res2010;70:1130-40 PMCID:PMC2943733

[65] Chakedis J,Babicky M.Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics.Oncotarget2016;7:45959-75 PMCID:PMC5216774

[66] Chakedis J,Babicky M.A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.Oncogene2016;35:3249-59 PMCID:PMC4837108

[67] Ciccolini J,Peters GJ.Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.Cancer Chemother Pharmacol2016;78:1-12 PMCID:PMC4921117

[68] Buxade M,Proud CG.The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases).Front Biosci2008;13:5359-73

[69] Scheper GC,Wilson M.The N and C termini of the splice variants of the human mitogen-activated protein kinase-interacting kinase Mnk2 determine activity and localization.Mol Cell Biol2003;23:5692-705 PMCID:PMC166352

[70] Calabretta S,Passacantilli I.Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.Oncogene2016;35:2031-9 PMCID:PMC4650269

[71] Jaramillo AC,Broekhuizen R.Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia.Nucleosides Nucleotides Nucleic Acids2020;39:1379-88

[72] Hubeek I,Broekhuizen AJ,Kaspers GJ.Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples.Nucleosides Nucleotides Nucleic Acids2008;27:787-93

[73] Lee SC,Kim E.Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.Nat Med2016;22:672-8 PMCID:PMC4899191

[74] Salton M.Small molecule modulators of Pre-mRNA splicing in cancer therapy.Trends Mol Med2016;22:28-37 PMCID:PMC4707101

[75] Lee SC.Therapeutic targeting of splicing in cancer.Nat Med2016;22:976-86 PMCID:PMC5644489

[76] Jyotsana N.Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.Expert Opin Ther Targets2018;22:107-21 PMCID:PMC7116745

[77] Giovannetti E,Mey V.Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.Cancer Res2006;66:3928-35

[78] Myers SN,Roy JD,Wilson JW.Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1.Pharmacogenet Genomics2006;16:315-20

[79] Supadmanaba IGP,Randazzo O.Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma.Epigenetics2021;1-21:

[80] Sankar S,Ponthan F.The SF3b splicing complex regulates DNA damage response in acute lymphoblastic leukemia.Blood2019;134:1237

[81] Firuzi O,El Hassouni B.Role of c-MET Inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells.Cancers (Basel)2019;11:638 PMCID:PMC6562408

[82] Hu CY,Hong B.Aberrant RON and MET co-overexpression as novel prognostic biomarkers of shortened patient survival and therapeutic targets of tyrosine kinase inhibitors in pancreatic cancer.Front Oncol2019;9:1377 PMCID:PMC6906148

[83] Giovannetti E.Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems.Expert Opin Drug Metab Toxicol2021;17:867-8